New York City, NY – According to filings with the U.S. Securities and Exchange Commission, Flame Biosciences is raising $15,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Harlan Weisman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. Our company was founded around a pipeline of assets with best in class potential to make a positive impact on patients with cancer driven by inflammation. Our idea is to develop the right therapy for patients with high inflammation. Our pipeline is currently focused on treating the life-threatening conditions of cancer, chronic kidney disease and other conditions that are driven by chronic inflammation.

To learn more about Flame Biosciences, visit http://flame.bio/

Contact:
Harlan Weisman, President and Chief Executive Officer
212-257-5802
https://www.linkedin.com/in/harlanweisman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved